- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Untreated Adult Acute Myeloid Leukemia
- Interventions
- cytarabine, daunorubicin hydrochloride, etoposide, valspodar
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 60 Years and older
- Enrollment
- 640 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2473–2496
of 5,327
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Small-cell Lung Cancer, Small Cell Lung Carcinoma
- Interventions
- Olaparib Pill 50 mg, Olaparib Pill 100 mg, Olaparib Pill 150 mg, Olaparib Pill 200 mg, Olaparib Pill 250 mg, Olaparib Pill 300 mg, Radiotherapy
- Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 9
- States / cities
- Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
- Conditions
- Severe Alopecia Areata
- Interventions
- Upadacitinib, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Miami, Florida • Meridian, Idaho + 6 more
- Conditions
- Solid Tumor
- Interventions
- rigosertib
- Drug
- Lead sponsor
- Traws Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Coronary Artery Disease
- Interventions
- PROMUS Coronary Stent System, PROMUS Element Coronary Stent System, Aspirin, Thienopyridine
- Device · Drug
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
- Conditions
- Heart Failure, Heart Failure Acute, Acute Cardiac Failure, Acute Cardiac Pulmonary Edema
- Interventions
- Nitrates, Loop Diuretics
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Nashville, Tennessee
- Conditions
- Pro-opiomelanocortin (POMC) Deficiency Obesity
- Interventions
- Setmelanotide, Placebo
- Drug
- Lead sponsor
- Rhythm Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Intrauterine Growth Retardation
- Interventions
- selective laser photocoagulation of communicating vessels, Expected Management
- Procedure · Device
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Tampa, Florida
- Conditions
- Subarachnoid Hemorrhage
- Interventions
- Sodium Nitrite
- Drug
- Lead sponsor
- Hope Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Abdominal Neoplasms, Pelvic Neoplasms
- Interventions
- Optison
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Schizophrenia
- Interventions
- Risperidone, Olanzapine, Lu AF35700
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,098 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 49
- States / cities
- Bellflower, California • Cerritos, California • Costa Mesa, California + 39 more
- Conditions
- Metastatic Cancer
- Interventions
- LY3007113
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 2
- States / cities
- Santa Monica, California • San Antonio, Texas
- Conditions
- MPN (Myeloproliferative Neoplasms)
- Interventions
- Pemigatinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Duarte, California • Stanford, California + 6 more
- Conditions
- Delirium, Sleep
- Interventions
- Dexmedetomidine, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 522 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Increase in Use of Immunization Registry, Increase in HPV Vaccination Rate
- Interventions
- Reminder Recall Report, Audit-Feedback/Immunization Forecasting Reports
- Other
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- Not listed
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Advanced Gastric Cancer
- Interventions
- Everolimus, Everolimus placebo, Best Supportive Care (BSC)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 656 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 8
- States / cities
- Fayetteville, Arkansas • Redlands, California • Detroit, Michigan + 5 more
- Conditions
- Dysbiosis, Gut -microbiota, Microbiome Analysis, Probiotic, Antibiotic Prophylaxis
- Interventions
- Placebo Capsule, Probiotic with Human Milk Oligosaccharides (HMO)
- Drug · Dietary Supplement
- Lead sponsor
- Acibadem Maslak Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Carboplatin, Nab-paclitaxel, MK-3475 (Phase I), MK-3475 (Phase II)
- Drug
- Lead sponsor
- Nisha Mohindra, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 5
- States / cities
- Duarte, California • Chicago, Illinois • Indianapolis, Indiana + 1 more
- Conditions
- Autistic Disorder, Autism, Asperger's Disorder, Asperger Syndrome, Autism Spectrum Disorders, Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)
- Interventions
- Memantine Hydrochloride (HCl), Placebo capsules
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 479 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 64
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more
- Conditions
- Atrial Fibrillation
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,504 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 66
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • East Palo Alto, California + 58 more
- Conditions
- Leukemia
- Interventions
- cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, imatinib mesylate, methotrexate, methylprednisolone, pegaspargase, vincristine sulfate
- Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Multiple Myeloma
- Interventions
- Recombinant glycosylated human interleukin-7, Melphalan, Autologous hematopoietic cell transplant
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage I Squamous Cell Carcinoma of the Oropharynx, Stage I Verrucous Carcinoma of the Oral Cavity, Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage II Squamous Cell Carcinoma of the Oropharynx, Stage II Verrucous Carcinoma of the Oral Cavity, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
- Interventions
- BRB Lozenge, Survey Administration, Laboratory Biomarker Analysis, pharmacological study
- Dietary Supplement · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- 5-Fluorouracil, Bevacizumab, Folinic acid, MEGF0444A, Oxaliplatin, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 18 more